Cargando…
Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis
In patients with heart failure (HF), iron deficiency (ID) is a well-recognized therapeutic target; information about its incidence, patterns of iron repletion, and clinical impact is scarce. This single-centre longitudinal cohort study assessed the rates of ID testing and diagnosis in patients with...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100536/ https://www.ncbi.nlm.nih.gov/pubmed/35566684 http://dx.doi.org/10.3390/jcm11092559 |
_version_ | 1784706869461254144 |
---|---|
author | Miñana, Gema Lorenzo, Miguel Ramirez de Arellano, Antonio Wächter, Sandra de la Espriella, Rafael Sastre, Clara Mollar, Anna Núñez, Eduardo Bodí, Vicent Sanchis, Juan Bayés-Genís, Antoni Núñez, Julio |
author_facet | Miñana, Gema Lorenzo, Miguel Ramirez de Arellano, Antonio Wächter, Sandra de la Espriella, Rafael Sastre, Clara Mollar, Anna Núñez, Eduardo Bodí, Vicent Sanchis, Juan Bayés-Genís, Antoni Núñez, Julio |
author_sort | Miñana, Gema |
collection | PubMed |
description | In patients with heart failure (HF), iron deficiency (ID) is a well-recognized therapeutic target; information about its incidence, patterns of iron repletion, and clinical impact is scarce. This single-centre longitudinal cohort study assessed the rates of ID testing and diagnosis in patients with stable HF, patterns of treatment with intravenous iron, and clinical impact of intravenous iron on HF rehospitalization risk. We included 711 consecutive outpatients (4400 visits) with stable chronic HF from 2014 to 2019 (median [interquartile range] visits per patient: 2 [2–7]. ID was defined as serum ferritin <100 µg/L, or 100–299 µg/L with transferrin saturation (TSAT) < 20%. During a median follow-up of 2.20 (1.11–3.78) years, ferritin and TSAT were measured at 2230 (50.7%) and 2183 visits (49.6%), respectively. ID was found at 846 (37.9%) visits, with ferritin and TSAT available (2230/4400), and intravenous iron was administered at 321/4400 (7.3%) visits; 233 (32.8%) patients received intravenous iron during follow-up. After multivariate analyses, iron repletion at any time during follow-up was associated with a lower risk of recurrent HF hospitalization (hazard ratio [HR] = 0.50, 95% confidence interval [CI] = 0.28–0.88; p = 0.016). Thus, ID was a frequent finding in patients with HF, and its repletion reduced the risk of recurrent HF hospitalizations. |
format | Online Article Text |
id | pubmed-9100536 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91005362022-05-14 Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis Miñana, Gema Lorenzo, Miguel Ramirez de Arellano, Antonio Wächter, Sandra de la Espriella, Rafael Sastre, Clara Mollar, Anna Núñez, Eduardo Bodí, Vicent Sanchis, Juan Bayés-Genís, Antoni Núñez, Julio J Clin Med Article In patients with heart failure (HF), iron deficiency (ID) is a well-recognized therapeutic target; information about its incidence, patterns of iron repletion, and clinical impact is scarce. This single-centre longitudinal cohort study assessed the rates of ID testing and diagnosis in patients with stable HF, patterns of treatment with intravenous iron, and clinical impact of intravenous iron on HF rehospitalization risk. We included 711 consecutive outpatients (4400 visits) with stable chronic HF from 2014 to 2019 (median [interquartile range] visits per patient: 2 [2–7]. ID was defined as serum ferritin <100 µg/L, or 100–299 µg/L with transferrin saturation (TSAT) < 20%. During a median follow-up of 2.20 (1.11–3.78) years, ferritin and TSAT were measured at 2230 (50.7%) and 2183 visits (49.6%), respectively. ID was found at 846 (37.9%) visits, with ferritin and TSAT available (2230/4400), and intravenous iron was administered at 321/4400 (7.3%) visits; 233 (32.8%) patients received intravenous iron during follow-up. After multivariate analyses, iron repletion at any time during follow-up was associated with a lower risk of recurrent HF hospitalization (hazard ratio [HR] = 0.50, 95% confidence interval [CI] = 0.28–0.88; p = 0.016). Thus, ID was a frequent finding in patients with HF, and its repletion reduced the risk of recurrent HF hospitalizations. MDPI 2022-05-02 /pmc/articles/PMC9100536/ /pubmed/35566684 http://dx.doi.org/10.3390/jcm11092559 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Miñana, Gema Lorenzo, Miguel Ramirez de Arellano, Antonio Wächter, Sandra de la Espriella, Rafael Sastre, Clara Mollar, Anna Núñez, Eduardo Bodí, Vicent Sanchis, Juan Bayés-Genís, Antoni Núñez, Julio Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis |
title | Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis |
title_full | Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis |
title_fullStr | Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis |
title_full_unstemmed | Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis |
title_short | Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis |
title_sort | incidence, treatment and clinical impact of iron deficiency in chronic heart failure: a longitudinal analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100536/ https://www.ncbi.nlm.nih.gov/pubmed/35566684 http://dx.doi.org/10.3390/jcm11092559 |
work_keys_str_mv | AT minanagema incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis AT lorenzomiguel incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis AT ramirezdearellanoantonio incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis AT wachtersandra incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis AT delaespriellarafael incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis AT sastreclara incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis AT mollaranna incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis AT nunezeduardo incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis AT bodivicent incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis AT sanchisjuan incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis AT bayesgenisantoni incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis AT nunezjulio incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis |